The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Peer review reports

Original Submission
25 Mar 2017	Submitted	Original manuscript
7 May 2017	Reviewed	Reviewer Report - Dereje Nigussie Woldemichael
9 May 2017	Reviewed	Reviewer Report - Esther Black
11 May 2017	Reviewed	Reviewer Report - Barbara Wiśniowska
22 May 2017	Author responded	Author comments - chih-jen yang
Resubmission - Version 2
22 May 2017	Submitted	Manuscript version 2
30 May 2017	Reviewed	Reviewer Report - Esther Black
31 May 2017	Reviewed	Reviewer Report - Barbara Wiśniowska
19 Jun 2017	Author responded	Author comments - chih-jen yang
Resubmission - Version 3
19 Jun 2017	Submitted	Manuscript version 3
31 Jul 2017	Author responded	Author comments - chih-jen yang
Resubmission - Version 4
31 Jul 2017	Submitted	Manuscript version 4
Publishing
5 Dec 2017	Editorially accepted
13 Dec 2017	Article published	10.1186/s40360-017-0190-1

Back to article page